Industry Research Reports

Home > Reports > Pharma & Healthcare > CD38 Monoclonal Antibody Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

CD38 Monoclonal Antibody Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-13

Pages: 101 Pages

Report ld: 2630539

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for CD38 Monoclonal Antibody Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for CD38 Monoclonal Antibody Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of CD38 Monoclonal Antibody Drugs by region & country, by Type, and by Application.

The CD38 Monoclonal Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (KG) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD38 Monoclonal Antibody Drugs.

Market Segmentation

Report Metric
Details
Report Title
CD38 Monoclonal Antibody Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global CD38 Monoclonal Antibody Drugs Companies Covered
Johnson, Sanofi, Takeda Pharmaceutical Company, CASI Pharmaceutical Company, Mab Biopharma
Global CD38 Monoclonal Antibody Drugs Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global CD38 Monoclonal Antibody Drugs Market, Segment by Type
Daretuzumab

Isartuximab

Engineered Toxin Body
Global CD38 Monoclonal Antibody Drugs Market, Segment by Application
Multiple Myeloma

Diffuse Large B Cell Lymphoma

Other
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CD38 Monoclonal Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of CD38 Monoclonal Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of CD38 Monoclonal Antibody Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 CD38 Monoclonal Antibody Drugs Product Introduction
    1.2 Global CD38 Monoclonal Antibody Drugs Market Size Forecast
        1.2.1 Global CD38 Monoclonal Antibody Drugs Sales Value (2019-2030)
        1.2.2 Global CD38 Monoclonal Antibody Drugs Sales Volume (2019-2030)
        1.2.3 Global CD38 Monoclonal Antibody Drugs Sales Price (2019-2030)
    1.3 CD38 Monoclonal Antibody Drugs Market Trends & Drivers
        1.3.1 CD38 Monoclonal Antibody Drugs Industry Trends
        1.3.2 CD38 Monoclonal Antibody Drugs Market Drivers & Opportunity
        1.3.3 CD38 Monoclonal Antibody Drugs Market Challenges
        1.3.4 CD38 Monoclonal Antibody Drugs Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global CD38 Monoclonal Antibody Drugs Players Revenue Ranking (2023)
    2.2 Global CD38 Monoclonal Antibody Drugs Revenue by Company (2019-2024)
    2.3 Global CD38 Monoclonal Antibody Drugs Players Sales Volume Ranking (2023)
    2.4 Global CD38 Monoclonal Antibody Drugs Sales Volume by Company Players (2019-2024)
    2.5 Global CD38 Monoclonal Antibody Drugs Average Price by Company (2019-2024)
    2.6 Key Manufacturers CD38 Monoclonal Antibody Drugs Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers CD38 Monoclonal Antibody Drugs Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of CD38 Monoclonal Antibody Drugs
    2.9 CD38 Monoclonal Antibody Drugs Market Competitive Analysis
        2.9.1 CD38 Monoclonal Antibody Drugs Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by CD38 Monoclonal Antibody Drugs Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD38 Monoclonal Antibody Drugs as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Daretuzumab
        3.1.2 Isartuximab
        3.1.3 Engineered Toxin Body
    3.2 Global CD38 Monoclonal Antibody Drugs Sales Value by Type
        3.2.1 Global CD38 Monoclonal Antibody Drugs Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global CD38 Monoclonal Antibody Drugs Sales Value, by Type (2019-2030)
        3.2.3 Global CD38 Monoclonal Antibody Drugs Sales Value, by Type (%) (2019-2030)
    3.3 Global CD38 Monoclonal Antibody Drugs Sales Volume by Type
        3.3.1 Global CD38 Monoclonal Antibody Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global CD38 Monoclonal Antibody Drugs Sales Volume, by Type (2019-2030)
        3.3.3 Global CD38 Monoclonal Antibody Drugs Sales Volume, by Type (%) (2019-2030)
    3.4 Global CD38 Monoclonal Antibody Drugs Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Multiple Myeloma
        4.1.2 Diffuse Large B Cell Lymphoma
        4.1.3 Other
    4.2 Global CD38 Monoclonal Antibody Drugs Sales Value by Application
        4.2.1 Global CD38 Monoclonal Antibody Drugs Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global CD38 Monoclonal Antibody Drugs Sales Value, by Application (2019-2030)
        4.2.3 Global CD38 Monoclonal Antibody Drugs Sales Value, by Application (%) (2019-2030)
    4.3 Global CD38 Monoclonal Antibody Drugs Sales Volume by Application
        4.3.1 Global CD38 Monoclonal Antibody Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global CD38 Monoclonal Antibody Drugs Sales Volume, by Application (2019-2030)
        4.3.3 Global CD38 Monoclonal Antibody Drugs Sales Volume, by Application (%) (2019-2030)
    4.4 Global CD38 Monoclonal Antibody Drugs Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global CD38 Monoclonal Antibody Drugs Sales Value by Region
        5.1.1 Global CD38 Monoclonal Antibody Drugs Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global CD38 Monoclonal Antibody Drugs Sales Value by Region (2019-2024)
        5.1.3 Global CD38 Monoclonal Antibody Drugs Sales Value by Region (2025-2030)
        5.1.4 Global CD38 Monoclonal Antibody Drugs Sales Value by Region (%), (2019-2030)
    5.2 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region
        5.2.1 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (2019-2024)
        5.2.3 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (2025-2030)
        5.2.4 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (%), (2019-2030)
    5.3 Global CD38 Monoclonal Antibody Drugs Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        5.4.2 North America CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        5.5.2 Europe CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        5.6.2 Asia Pacific CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        5.7.2 South America CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        5.8.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value
        6.2.1 Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        6.2.2 Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        6.3.2 United States CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        6.4.2 Europe CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        6.5.2 China CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
        6.5.3 China CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        6.6.2 Japan CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        6.7.2 South Korea CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        6.8.2 Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
        6.9.2 India CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
        6.9.3 India CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Johnson
        7.1.1 Johnson Company Information
        7.1.2 Johnson Introduction and Business Overview
        7.1.3 Johnson CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Johnson CD38 Monoclonal Antibody Drugs Product Offerings
        7.1.5 Johnson Recent Development
    7.2 Sanofi
        7.2.1 Sanofi Company Information
        7.2.2 Sanofi Introduction and Business Overview
        7.2.3 Sanofi CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Sanofi CD38 Monoclonal Antibody Drugs Product Offerings
        7.2.5 Sanofi Recent Development
    7.3 Takeda Pharmaceutical Company
        7.3.1 Takeda Pharmaceutical Company Company Information
        7.3.2 Takeda Pharmaceutical Company Introduction and Business Overview
        7.3.3 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offerings
        7.3.5 Takeda Pharmaceutical Company Recent Development
    7.4 CASI Pharmaceutical Company
        7.4.1 CASI Pharmaceutical Company Company Information
        7.4.2 CASI Pharmaceutical Company Introduction and Business Overview
        7.4.3 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offerings
        7.4.5 CASI Pharmaceutical Company Recent Development
    7.5 Mab Biopharma
        7.5.1 Mab Biopharma Company Information
        7.5.2 Mab Biopharma Introduction and Business Overview
        7.5.3 Mab Biopharma CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Mab Biopharma CD38 Monoclonal Antibody Drugs Product Offerings
        7.5.5 Mab Biopharma Recent Development

 8 Industry Chain Analysis
    8.1 CD38 Monoclonal Antibody Drugs Industrial Chain
    8.2 CD38 Monoclonal Antibody Drugs Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 CD38 Monoclonal Antibody Drugs Sales Model
        8.5.2 Sales Channel
        8.5.3 CD38 Monoclonal Antibody Drugs Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. CD38 Monoclonal Antibody Drugs Market Trends
    Table 2. CD38 Monoclonal Antibody Drugs Market Drivers & Opportunity
    Table 3. CD38 Monoclonal Antibody Drugs Market Challenges
    Table 4. CD38 Monoclonal Antibody Drugs Market Restraints
    Table 5. Global CD38 Monoclonal Antibody Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Global CD38 Monoclonal Antibody Drugs Sales Volume by Company (2019-2024) & (KG)
    Table 8. Global CD38 Monoclonal Antibody Drugs Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market CD38 Monoclonal Antibody Drugs Price by Company (2019-2024) & (US$/g)
    Table 10. Key Manufacturers CD38 Monoclonal Antibody Drugs Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers CD38 Monoclonal Antibody Drugs Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of CD38 Monoclonal Antibody Drugs
    Table 13. Global CD38 Monoclonal Antibody Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD38 Monoclonal Antibody Drugs as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global CD38 Monoclonal Antibody Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global CD38 Monoclonal Antibody Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global CD38 Monoclonal Antibody Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global CD38 Monoclonal Antibody Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global CD38 Monoclonal Antibody Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global CD38 Monoclonal Antibody Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (KG)
    Table 22. Global CD38 Monoclonal Antibody Drugs Sales Volume by Type (2019-2024) & (KG)
    Table 23. Global CD38 Monoclonal Antibody Drugs Sales Volume by Type (2025-2030) & (KG)
    Table 24. Global CD38 Monoclonal Antibody Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global CD38 Monoclonal Antibody Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global CD38 Monoclonal Antibody Drugs Price by Type (2019-2024) & (US$/g)
    Table 27. Global CD38 Monoclonal Antibody Drugs Price by Type (2025-2030) & (US$/g)
    Table 28. Global CD38 Monoclonal Antibody Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global CD38 Monoclonal Antibody Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global CD38 Monoclonal Antibody Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global CD38 Monoclonal Antibody Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global CD38 Monoclonal Antibody Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global CD38 Monoclonal Antibody Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (KG)
    Table 34. Global CD38 Monoclonal Antibody Drugs Sales Volume by Application (2019-2024) & (KG)
    Table 35. Global CD38 Monoclonal Antibody Drugs Sales Volume by Application (2025-2030) & (KG)
    Table 36. Global CD38 Monoclonal Antibody Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global CD38 Monoclonal Antibody Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global CD38 Monoclonal Antibody Drugs Price by Application (2019-2024) & (US$/g)
    Table 39. Global CD38 Monoclonal Antibody Drugs Price by Application (2025-2030) & (US$/g)
    Table 40. Global CD38 Monoclonal Antibody Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global CD38 Monoclonal Antibody Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global CD38 Monoclonal Antibody Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global CD38 Monoclonal Antibody Drugs Sales Value by Region (2019-2024) & (%)
    Table 44. Global CD38 Monoclonal Antibody Drugs Sales Value by Region (2025-2030) & (%)
    Table 45. Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (KG): 2019 VS 2023 VS 2030
    Table 46. Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (2019-2024) & (KG)
    Table 47. Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (2025-2030) & (KG)
    Table 48. Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (2019-2024) & (%)
    Table 49. Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (2025-2030) & (%)
    Table 50. Global CD38 Monoclonal Antibody Drugs Average Price by Region (2019-2024) & (US$/g)
    Table 51. Global CD38 Monoclonal Antibody Drugs Average Price by Region (2025-2030) & (US$/g)
    Table 52. Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Volume, (2019-2024) & (KG)
    Table 56. Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Volume, (2025-2030) & (KG)
    Table 57. Johnson Company Information
    Table 58. Johnson Introduction and Business Overview
    Table 59. Johnson CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
    Table 60. Johnson CD38 Monoclonal Antibody Drugs Product Offerings
    Table 61. Johnson Recent Development
    Table 62. Sanofi Company Information
    Table 63. Sanofi Introduction and Business Overview
    Table 64. Sanofi CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
    Table 65. Sanofi CD38 Monoclonal Antibody Drugs Product Offerings
    Table 66. Sanofi Recent Development
    Table 67. Takeda Pharmaceutical Company Company Information
    Table 68. Takeda Pharmaceutical Company Introduction and Business Overview
    Table 69. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
    Table 70. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offerings
    Table 71. Takeda Pharmaceutical Company Recent Development
    Table 72. CASI Pharmaceutical Company Company Information
    Table 73. CASI Pharmaceutical Company Introduction and Business Overview
    Table 74. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
    Table 75. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offerings
    Table 76. CASI Pharmaceutical Company Recent Development
    Table 77. Mab Biopharma Company Information
    Table 78. Mab Biopharma Introduction and Business Overview
    Table 79. Mab Biopharma CD38 Monoclonal Antibody Drugs Sales (KG), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
    Table 80. Mab Biopharma CD38 Monoclonal Antibody Drugs Product Offerings
    Table 81. Mab Biopharma Recent Development
    Table 82. Key Raw Materials Lists
    Table 83. Raw Materials Key Suppliers Lists
    Table 84. CD38 Monoclonal Antibody Drugs Downstream Customers
    Table 85. CD38 Monoclonal Antibody Drugs Distributors List
    Table 86. Research Programs/Design for This Report
    Table 87. Key Data Information from Secondary Sources
    Table 88. Key Data Information from Primary Sources
List of Figures
    Figure 1. CD38 Monoclonal Antibody Drugs Product Picture
    Figure 2. Global CD38 Monoclonal Antibody Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global CD38 Monoclonal Antibody Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global CD38 Monoclonal Antibody Drugs Sales Volume (2019-2030) & (KG)
    Figure 5. Global CD38 Monoclonal Antibody Drugs Sales Price (2019-2030) & (US$/g)
    Figure 6. CD38 Monoclonal Antibody Drugs Report Years Considered
    Figure 7. Global CD38 Monoclonal Antibody Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global CD38 Monoclonal Antibody Drugs Players Sales Volume Ranking (2023) & (KG)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by CD38 Monoclonal Antibody Drugs Revenue in 2023
    Figure 10. CD38 Monoclonal Antibody Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Daretuzumab Picture
    Figure 12. Isartuximab Picture
    Figure 13. Engineered Toxin Body Picture
    Figure 14. Global CD38 Monoclonal Antibody Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global CD38 Monoclonal Antibody Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Global CD38 Monoclonal Antibody Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (KG)
    Figure 17. Global CD38 Monoclonal Antibody Drugs Sales Volume Market Share by Type, 2023 & 2030
    Figure 18. Global CD38 Monoclonal Antibody Drugs Price by Type (2019-2030) & (US$/g)
    Figure 19. Product Picture of Multiple Myeloma
    Figure 20. Product Picture of Diffuse Large B Cell Lymphoma
    Figure 21. Product Picture of Other
    Figure 22. Global CD38 Monoclonal Antibody Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global CD38 Monoclonal Antibody Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 24. Global CD38 Monoclonal Antibody Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (KG)
    Figure 25. Global CD38 Monoclonal Antibody Drugs Sales Volume Market Share by Application, 2023 & 2030
    Figure 26. Global CD38 Monoclonal Antibody Drugs Price by Application (2019-2030) & (US$/g)
    Figure 27. North America CD38 Monoclonal Antibody Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 28. North America CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 29. Europe CD38 Monoclonal Antibody Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 30. Europe CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 31. Asia Pacific CD38 Monoclonal Antibody Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 33. South America CD38 Monoclonal Antibody Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 34. South America CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 35. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 36. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 37. Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value (%), (2019-2030)
    Figure 38. Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Volume (%), (2019-2030)
    Figure 39. United States CD38 Monoclonal Antibody Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 40. United States CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 41. United States CD38 Monoclonal Antibody Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 42. Europe CD38 Monoclonal Antibody Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Europe CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 44. Europe CD38 Monoclonal Antibody Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 45. China CD38 Monoclonal Antibody Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 46. China CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 47. China CD38 Monoclonal Antibody Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 48. Japan CD38 Monoclonal Antibody Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Japan CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 50. Japan CD38 Monoclonal Antibody Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 51. South Korea CD38 Monoclonal Antibody Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 52. South Korea CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 53. South Korea CD38 Monoclonal Antibody Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 54. Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 56. Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 57. India CD38 Monoclonal Antibody Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 58. India CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 59. India CD38 Monoclonal Antibody Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 60. CD38 Monoclonal Antibody Drugs Industrial Chain
    Figure 61. CD38 Monoclonal Antibody Drugs Manufacturing Cost Structure
    Figure 62. Channels of Distribution (Direct Sales, and Distribution)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed

Description

The global market for CD38 Monoclonal Antibody Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for CD38 Monoclonal Antibody Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of CD38 Monoclonal Antibody Drugs by region & country, by Type, and by Application.

The CD38 Monoclonal Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (KG) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD38 Monoclonal Antibody Drugs.

Market Segmentation